Restrictive Cardiomyopathy

Overview

Restrictive cardiomyopathy is a disease of the heart muscle in which the muscle becomes abnormally stiff and loses its normal flexibility. In this condition, the heart's ability to contract may be preserved for some time, but the heart chambers cannot expand adequately during diastole, the relaxation phase between beats. Because the chambers cannot fill properly with blood, the amount of blood pumped to the body with each beat is reduced.

Restrictive cardiomyopathy is the least common type of cardiomyopathy. However, it can be among the most serious in terms of its impact on heart function and overall prognosis. By the time symptoms become apparent, the disease is often already at an advanced stage. Early diagnosis is therefore particularly important.

Several distinct underlying causes have been identified. In some cases, an abnormal substance accumulates within the heart muscle and stiffens it. In others, normal muscle tissue is progressively replaced by scar or fibrous tissue. Identifying the specific cause is critical, as some forms have effective targeted therapies that can slow or even partially reverse the disease.

Symptoms

The symptoms of restrictive cardiomyopathy can begin gradually and progress slowly over time. Some people may have no noticeable symptoms for an extended period. The type and severity of symptoms can vary considerably from one person to another.

• Shortness of breath. This is one of the most common symptoms. It may first appear only during physical exertion, such as climbing stairs or walking briskly. Over time, breathlessness can also occur at rest or when lying flat.
• Fatigue and weakness. A persistent, unexplained sense of exhaustion may develop. Activities that were previously manageable may begin to feel more effortful than usual.
• Swelling in the legs and ankles. Swelling in the legs and ankles may be noticed, often worsening as the day progresses. A feeling of fullness or enlargement in the abdominal area can also develop.
• Palpitations or irregular heartbeat. The heart may feel as though it is racing, fluttering, or beating irregularly.
• Dizziness or lightheadedness. A feeling of unsteadiness or dizziness may occasionally occur.
• Chest discomfort. Some people may notice a feeling of pressure or tightness in the chest.

When to Seek Medical Care

See a doctor if you notice any of the following.

• Shortness of breath during activity or at rest
• Swelling in the legs, ankles, or abdomen
• Unexplained and worsening fatigue
• Palpitations or a sensation of irregular heartbeat
• Abdominal enlargement or a feeling of fullness

Call emergency services immediately if you experience any of the following.

• Sudden and severe shortness of breath
• Sudden, severe chest pain
• Fainting or nearly fainting
• A very rapid or markedly irregular heartbeat

Causes

Restrictive cardiomyopathy can result from several distinct underlying conditions. Identifying the specific cause is one of the most important steps in management, as some causes have effective targeted treatments that can alter the course of the disease.

• Amyloidosis. This is one of the most common causes. Abnormally folded proteins accumulate in the heart muscle, stiffening it. There are two main types relevant to the heart. AL amyloidosis is caused by abnormal plasma cells in the bone marrow producing abnormal light chain proteins. It can follow a rapid course. ATTR amyloidosis results from abnormal folding of a protein called transthyretin. It has both an age-related form, which predominantly affects older men, and an inherited form caused by a gene change. Effective targeted therapies for ATTR amyloidosis have become available in recent years and have transformed the management of this condition.
• Sarcoidosis. When the immune system becomes abnormally activated, clusters of inflammatory cells can form in various organs. When these clusters involve the heart muscle, they can produce a restrictive picture alongside serious rhythm disturbances. Corticosteroids and other immune-modulating medications can be effective in some patients.
• Hemochromatosis. This condition involves excessive iron accumulation throughout the body, including in the heart muscle. When identified early and treated with regular blood removal or iron chelation therapy, heart function can improve.
• Endomyocardial fibrosis. Fibrous tissue develops along the inner surface of the heart chambers, significantly restricting their ability to fill. This form is more common in tropical regions, particularly in parts of Africa, and is uncommon elsewhere.
• Loeffler endocarditis. This condition is associated with elevated levels of a type of white blood cell called an eosinophil. These cells can infiltrate the heart muscle and cause damage and fibrosis.
• Radiation-induced disease. Radiotherapy delivered to the chest, such as for lymphoma or breast cancer, can damage the heart muscle and pericardium over time, eventually producing a restrictive pattern.
• Idiopathic restrictive cardiomyopathy. In some cases, no definitive cause is identified despite thorough investigation. These cases are classified as idiopathic.

Risk Factors

• Older age. Age-related ATTR amyloidosis is considerably more common in men over 65. Restrictive cardiomyopathy overall is more frequently encountered in middle-aged and older adults.
• Family history of amyloidosis. In hereditary ATTR amyloidosis, the gene change is passed through families. Having an affected family member warrants evaluation of other first-degree relatives.
• Known hemochromatosis or sarcoidosis. People with these conditions require monitoring for cardiac involvement.
• Prior chest radiotherapy. People who have received radiation to the chest, particularly for lymphoma or breast cancer, face an increased long-term risk of restrictive cardiomyopathy and other cardiac complications.

Diagnosis

Restrictive cardiomyopathy can be challenging to diagnose because its symptoms and findings overlap considerably with other heart conditions, most notably constrictive pericarditis, which requires a very different treatment. Accurate diagnosis is essential both for guiding treatment and for avoiding interventions that are ineffective or potentially harmful.

• Medical history and physical examination. The doctor asks in detail about when symptoms began and how they have progressed. A family history of amyloidosis, hemochromatosis, or unexplained heart failure is specifically important. Any history of chemotherapy or chest radiation should be mentioned. On examination, the doctor listens to the heart and lungs, assesses neck vein distension, checks for liver enlargement, and looks for signs of fluid in the abdomen. Physical signs outside the heart can also be informative in suspected amyloidosis. Enlargement of the tongue, purple bruising around the eyes, and carpal tunnel syndrome are findings that can point strongly toward amyloidosis even before cardiac testing.
• Echocardiogram (heart ultrasound). This is the cornerstone of the diagnostic evaluation. It shows the size of the heart chambers, the thickness of the walls, and, critically, how the chambers fill. In restrictive cardiomyopathy, the left ventricle size and contraction may initially be preserved, but filling abnormalities are pronounced and detectable using Doppler measurements. In amyloidosis, the heart muscle may take on a characteristic granular or sparkling appearance on ultrasound. Left atrial enlargement and valve function are also assessed. Tissue Doppler measurements of filling velocities provide important diagnostic information and help distinguish restrictive cardiomyopathy from constrictive pericarditis.
• Electrocardiogram (ECG). The ECG is usually abnormal in restrictive cardiomyopathy. A particularly characteristic finding in amyloidosis is low voltage, meaning the electrical signals are unexpectedly weak despite the presence of a thickened heart muscle. Conduction abnormalities, atrial fibrillation, and other rhythm disturbances may also be seen. The combination of a thickened heart on echocardiography with low voltage on ECG is a hallmark pattern that strongly suggests amyloidosis.
• Cardiac MRI. This provides the most detailed assessment of the heart muscle's structure and composition. In amyloidosis, late gadolinium enhancement shows a characteristic widespread pattern that strongly supports the diagnosis. In sarcoidosis, focal areas of inflammation and scarring can be identified. Cardiac MRI is one of the most valuable tools for distinguishing restrictive cardiomyopathy from constrictive pericarditis, as the two conditions require fundamentally different treatments.
• Nuclear scintigraphy. This imaging technique is highly valuable for differentiating ATTR amyloidosis from AL amyloidosis and from other causes of restrictive cardiomyopathy. A radioactive tracer, such as pyrophosphate or DPD, is injected and its uptake in the heart is imaged. In ATTR amyloidosis, there is characteristically intense uptake in the heart muscle. This test can diagnose ATTR amyloidosis non-invasively with high accuracy in the right clinical context.
• Blood and urine tests. In AL amyloidosis, abnormal immunoglobulin light chains can be detected in the blood and urine. Serum and urine protein electrophoresis and a free light chain assay are used for this purpose. Genetic analysis of the transthyretin gene can identify hereditary ATTR amyloidosis. BNP and NT-proBNP levels reflect the severity of heart failure. Iron studies and ferritin levels are assessed when hemochromatosis is suspected.
• Biopsy. In some patients, a tissue sample is needed to confirm the diagnosis. In suspected amyloidosis, non-cardiac biopsy sites are preferred first. Abdominal fat pad biopsy and minor salivary gland biopsy are commonly used options. In patients with typical echocardiographic and scintigraphic findings for ATTR amyloidosis, biopsy can often be avoided. Cardiac biopsy is reserved for more complex situations where the diagnosis cannot be established by non-invasive means.
• Holter monitor. A portable ECG device worn for 24 hours or longer to record rhythm disturbances during normal daily activity. Because atrial fibrillation, conduction problems, and ventricular arrhythmias are common in restrictive cardiomyopathy, Holter monitoring is an important part of the evaluation.

Treatment

Treatment of restrictive cardiomyopathy is organized around two parallel aims. The first is specific therapy directed at the underlying cause. The second is the management of heart failure symptoms and complications. Identifying the cause correctly is the single most important determinant of treatment success in this condition.

Treatments Targeting the Underlying Cause

• Tafamidis for ATTR amyloidosis. Tafamidis works as a transthyretin stabilizer, preventing the transthyretin protein from misfiling and depositing in the heart muscle. Clinical trials have demonstrated that tafamidis significantly reduces heart failure hospitalizations and cardiovascular death in patients with ATTR cardiac amyloidosis. The best response is seen when treatment is started early. In eligible patients, tafamidis should be initiated as soon as possible after diagnosis.
• Chemotherapy for AL amyloidosis. Because AL amyloidosis arises from abnormal plasma cells in the bone marrow producing abnormal light chain proteins, chemotherapy protocols targeting these cells form the basis of treatment. Autologous stem cell transplantation may also be considered in selected patients. The goal is to suppress abnormal protein production and halt further deposition in the heart and other organs.
• Immunosuppressive therapy for sarcoidosis. Corticosteroids are the first-line treatment for cardiac sarcoidosis. They suppress the inflammatory process and can slow progression of damage to the heart muscle. When adequate response is not achieved or when long-term corticosteroid use is not appropriate, medications such as azathioprine or methotrexate may be added.
• Iron removal therapy for hemochromatosis. Regular therapeutic blood removal is used to reduce excess iron from the body. When initiated early, this approach can meaningfully improve heart function. Iron chelation medications are an alternative for patients who are unable to undergo regular phlebotomy.

Managing Heart Failure Symptoms

Heart failure management in restrictive cardiomyopathy requires a more careful and individualized approach than in dilated cardiomyopathy. Some medications that are standard in other forms of heart failure must be used with particular caution in the restrictive setting.

• Diuretics. These are the most commonly used and most reliably effective symptomatic treatment in restrictive cardiomyopathy. By removing excess fluid from the body, they relieve breathlessness and reduce swelling. Dosing requires careful adjustment, however. Excessive fluid removal can further impair cardiac filling and worsen the condition rather than improve it.
• Heart rate control. Because the stiff heart depends heavily on having adequate time to fill between beats, a heart rate that is too fast significantly compromises filling and worsens the condition. Rate-controlling medications are used in some patients. The specific choice must be made carefully based on the underlying cause and the individual's clinical situation.
• Atrial fibrillation management. Atrial fibrillation is common in restrictive cardiomyopathy and both worsens symptoms and increases the risk of stroke through clot formation. Rate control and blood-thinning therapy are generally required. Attempts to restore and maintain normal rhythm with medications or electrical cardioversion may be considered.
• Blood thinners. Used to reduce the risk of clot formation and stroke when atrial fibrillation is present.

Managing Rhythm Disturbances

• Implantable cardioverter-defibrillator (ICD). In sarcoidosis-related restrictive cardiomyopathy, life-threatening ventricular arrhythmias can develop, and an ICD is an effective means of protection against sudden cardiac arrest. In amyloidosis-related restrictive cardiomyopathy, the ICD decision requires a more individualized risk assessment.
• Pacemaker. Advanced conduction system disease or complete heart block, which are seen particularly in cardiac sarcoidosis, may require pacemaker implantation.

Advanced Treatments

• Heart transplantation. In end-stage restrictive cardiomyopathy that does not respond to other treatments, heart transplantation may be considered. In systemic diseases such as amyloidosis, however, the transplant decision requires particular care. If the systemic disease is not controlled, the abnormal protein or substance can accumulate in the new heart as well, limiting the benefit of transplantation.

Complications

Restrictive cardiomyopathy can lead to serious complications over time. The course of the disease varies depending on the underlying cause but generally follows a progressive pattern.

• Advanced heart failure. This is the most common and most consequential complication. As the heart chambers become progressively less able to fill, the body's demand for blood cannot be met. Breathlessness, swelling, and fatigue worsen over time.
• Atrial fibrillation and rhythm disturbances. The elevated pressures resulting from the stiff heart muscle cause the upper chambers to enlarge, predisposing to atrial fibrillation. In sarcoidosis-related cases, ventricular arrhythmias and sudden cardiac arrest risk may be prominent.
• Stroke and thromboembolic events. Clots forming in the heart as a result of atrial fibrillation can travel to the brain and cause a stroke. Appropriate blood-thinning therapy can significantly reduce this risk.
• Multi-organ involvement. In systemic diseases such as amyloidosis and hemochromatosis, organs beyond the heart are also affected. Kidney failure, liver involvement, and nervous system damage may accompany the cardiac disease. Treatment must therefore be planned to address the whole body, not only the heart.

Lifestyle

Restrictive cardiomyopathy requires lifelong attention and monitoring. The treatment course varies with the underlying cause, but certain general principles apply broadly.

Salt and Fluid Intake

Salt causes the body to retain fluid and increases the strain on the heart. Reducing daily salt intake can meaningfully relieve breathlessness and swelling, particularly in patients with leg edema. Processed foods, canned goods, and ready-made meals tend to be high in sodium. Ask your doctor for a specific daily salt target appropriate to your situation. In some patients, total fluid intake may also need to be restricted.

Daily Weight Monitoring

Weighing yourself at the same time each morning and recording the result is one of the most practical tools for detecting fluid accumulation before symptoms worsen significantly. A gain of two to three pounds or more over a short period can indicate that fluid is building up. Contact your doctor if this happens. Ask your care team at what point a weight gain should prompt you to call or seek care.

Physical Activity

Exercise capacity is generally reduced in restrictive cardiomyopathy, and the appropriate level of activity varies considerably between individuals and underlying causes. Light activities such as gentle walking may be suitable for many patients, but the specific type and intensity of exercise that is safe for you should be determined by your doctor. Strenuous effort and activities that require sudden bursts of exertion are generally best avoided.

Medications

Treatment typically requires long-term or lifelong medication use. Taking medications consistently and not stopping them without medical guidance is essential. If a side effect is troubling you, speak with your doctor rather than discontinuing the medication independently. Before starting any new medication for any condition, always inform the prescribing doctor about your heart condition and current medications. In amyloidosis in particular, certain commonly used drugs can worsen the condition and must be avoided.

Monitoring the Underlying Condition

When restrictive cardiomyopathy results from a systemic disease such as amyloidosis, sarcoidosis, or hemochromatosis, monitoring the underlying condition is as important as monitoring the heart. Kidney function, liver values, and the status of other affected organs should be assessed regularly. Keeping the systemic disease under control also protects the heart.

Informing Family Members

In inherited forms of restrictive cardiomyopathy, particularly hereditary ATTR amyloidosis, first-degree relatives should be referred for cardiology and genetic evaluation. Early diagnosis in this condition allows treatment to begin during the phase when it is most effective.

Regular Follow-up

Restrictive cardiomyopathy requires frequent monitoring. Echocardiography, ECG, and blood tests are used at regular intervals to track heart function and assess the response to treatment. Do not miss follow-up appointments. Contact your doctor promptly or seek emergency care if any of the following develop.

• Shortness of breath that returns or worsens
• Swelling in the legs or abdomen that is new or increasing
• A gain of several pounds over a short period
• Palpitations or a sensation of irregular heartbeat
• Dizziness or fainting
• Chest pain or pressure

Preparing for Your Appointment

Coming prepared to an appointment for restrictive cardiomyopathy helps your doctor make a more accurate assessment and choose the most appropriate treatment for you.

What You Can Do

• Write down when symptoms began and how they have progressed over time.
• Mention any family history of amyloidosis, hemochromatosis, or unexplained heart failure.
• Report any history of chemotherapy or chest radiation.
• List all medications, supplements, and herbal products you are currently taking.
• Bring any home weight or blood pressure readings you have recorded.
• Write your questions down before the appointment.

Questions You May Wish to Ask Your Doctor

• What is causing my restrictive cardiomyopathy?
• Could amyloidosis or another systemic disease be the underlying cause?
• Is there a specific targeted treatment available for my type?
• Which medications do I need and for how long?
• Do I need an implantable device?
• Should my family members be evaluated?
• What type and amount of physical activity is safe for me?
• Which symptoms should prompt me to seek emergency care?
• How often do I need follow-up appointments?

Questions Your Doctor May Ask You

• When did symptoms begin and how have they progressed?
• Is there a family history of amyloidosis, hemochromatosis, or unexplained heart failure?
• Have you received chemotherapy or radiation to the chest?
• Have you experienced carpal tunnel syndrome or shoulder pain?
• Have you noticed any changes around your eyes or on your skin?
• What medications are you currently taking?
• Do you have any other known systemic conditions?